You are here: Industry Insights > Janssen

News List

Janssen Issues Recall for ORTHO-NOVUM 1/35, ORTHO-NOVUM 7/7/7 americanpharmaceuticalreview
November 07, 2018
Janssen Issues Recall for ORTHO-NOVUM 1/35, ORTHO-NOVUM 7/7/7
Yuhan licences lung cancer asset to Janssen in $1.25bn deal pharmaceutical-technology
November 06, 2018
South Korean pharmaceutical company Yuhan has signed a licensing and cooperation agreement valued at up to $1.25bn with Janssen Biotech to out-license a lung cancer drug candidate called Lazertinib.
Janssen Receives FDA Approval for INVOKANA contractpharma
November 01, 2018
To reduce risk of major adverse cardiovascular events, in adults with type 2 diabetes (T2D) who have established CV disease
Janssen gets FDA approval for Invokana to reduce risk of CV events pharmaceutical-technology
November 01, 2018
Janssen Pharmaceutical has received approval from the US Food and Drug Administration (FDA) for the use of Invokana (canagliflozin) to minimise the risk of major adverse cardiovascular (CV) events in adults.
Janssen files nasal spray for depression pharmatimes
October 12, 2018
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
Stelara induces remission in ulcerative colitis patients pharmatimes
October 11, 2018
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.
Janssen’s first-of-its-kind report combats blood cancer myths in APAC biospectrumasia
September 17, 2018
The report was developed by the Janssen Pharmaceutical Companies of Johnson & Johnson and supported by The Max Foundation.
Janssen bags new EU approval for Darzalex pharmatimes
September 14, 2018
Janssen’s Darzalex has been approved in Europe for the first-line treatment of patients with multiple myeloma.
Janssen and ViiV report positive results for two drug regimen for HIV-1 pharmaceutical-technology
August 17, 2018
Johnson & Johnson subsidiary Janseen Pharmaceuticals and ViiV Healthcare have reported positive topline results from their phase III trial of an investigational long-acting injectable two drug regimen for the treatment of human immunodeficiency virus-1 (H
Janssen and ViiV's monthly injectable HIV combo proves non-inferior to daily standard of care pharmafile
August 16, 2018
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, for the treatment of HIV-1, demonstrating similar efficacy to a standard daily, oral three-drug regimen over a 48 week period, meeting

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page